摘要
目的探讨单用羟喜树碱(hydroxycamptothecin,HCPT)膀胱内灌注与羟基喜树碱联合卡介苗(HCPT+BCG)膀胱腔内灌注对肾盂癌根治术后患者预后及肿瘤复发的影响。方法 121例肾盂癌患者行后腹腔镜下肾盂癌根治术后分为两组:组1为单用HCPT组(58例),术后单用HCPT定期膀胱腔内灌注治疗;组2为HCPT+BCG组(63例),术后1周内单次HCPT膀胱腔内灌注,第2周后开始定期卡介苗膀胱腔内灌注。术后定期膀胱镜等检查和随访。统计学分析两组患者的预后及复发情况。结果HCPT+BCG组患者的生存期显著高于单用HCPT组,且复发率显著降低(P<0.05)。两组患者在灌注中及灌注后均无明显不良反应及并发症。结论羟基喜树碱联合卡介苗膀胱腔内灌注对预防后腹腔镜下肾盂癌根治术后复发疗效肯定,有良好的临床应用价值。
Objective To evaluate intravesical instillation of hydroxycamptothecin combined with BCG to prevent recurrence of renal pelvic carcinoma after radical resection of carcinoma of the renal pelvis. Methods121 cases of renal pelvic carcinoma underwent radical resection of carcinoma of the renal pelvis were divided into2 groups. Group 1 received Hydroxycamptothecin alone（ 58 cases）. Within 1 week after radical resection of carcinoma of the renal pelvis. Group 2 received intravesical instillation of hydroxycamptothecin combined with BCG（ 63 cases）. Within 1 week following operation single dose of intravesical Hydroxycamptothecin instillation was given and from the second week regular intravesical BCG was instilled afterwards. All the patients were followed up for 36 months. Results The recurrence rate was significantly different between the 2 groups（ P 〈 0. 05）. No serious side effect and complication developed either during or after instillation in both groups. Conclusions Single dose intravesical hydroxycamptothecin instillation combined with subsequent intravesical BCG instillation is significantly effective for preventing the recurrence of transitional renal pelvic carcinoma after radical resection of carcinoma of the renal pelvis. This therapy is of higher clinical value.
出处
《泌尿外科杂志（电子版）》
2017年第2期24-27,共4页
Journal of Urology for Clinicians(Electronic Version)
关键词
肾盂癌
羟喜树碱
卡介苗
灌注法
Renal pelvic carcinoma
Hydroxycamptothecin
BCG
Intravesical instillation
